Publications:

Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.

Plos One

Chow, Yock Ping YP; Zainul Abidin, Norziha N; Kow, Ken Siong KS; Tho, Lye Mun LM; Wong, Chieh Lee CL

Publication Date: 2022

Variant appearance in text: EGFR: 2525A>T

PubMed Link: 36256645

Variant Present in the following documents:

• pone.0276161.s002.xlsx, sheet 1

View BVdb publication page

Multilaboratory Assessment of a New Reference Material for Quality Assurance of Cell-Free Tumor DNA Measurements.

The Journal Of Molecular Diagnostics : Jmd

He, Hua-Jun HJ; Stein, Erica V EV; Konigshofer, Yves Y; Forbes, Thomas T; Tomson, Farol L FL; Garlick, Russell R; Yamada, Emiko E; Godfrey, Tony T; Abe, Toshiya T; Tamura, Koji K; Borges, Michael M; Goggins, Michael M; Elmore, Sandra S; Gulley, Margaret L ML; Larson, Jessica L JL; Ringel, Lando L; Haynes, Brian C BC; Karlovich, Chris C; Williams, P Mickey PM; Garnett, Aaron A; Ståhlberg, Anders A; Filges, Stefan S; Sorbara, Lynn L; Young, Mathew R MR; Srivastava, Sudhir S; Cole, Kenneth D KD

Publication Date: 2019-07

Variant appearance in text: EGFR: 2525A>T

PubMed Link: 31055023

Variant Present in the following documents:

• Main text

View BVdb publication page

Olaparib is effective in combination with, and as maintenance therapy after, first-line endocrine therapy in prostate cancer cells.

Molecular Oncology

Feiersinger, Gertrud E GE; Trattnig, Kristina K; Leitner, Peter D PD; Guggenberger, Fabian F; Oberhuber, Alexander A; Peer, Sarah S; Hermann, Martin M; Skvortsova, Ira I; Vrbkova, Jana J; Bouchal, Jan J; Culig, Zoran Z; Santer, Frédéric R FR

Publication Date: 2018-04

Variant appearance in text: EGFR: 2525A>T; N842I

PubMed Link: 29465803

Variant Present in the following documents:

• MOL2-12-561-s006.xlsx, sheet 7

View BVdb publication page

Erlotinib is effective in pancreatic cancer with epidermal growth factor receptor mutations: a randomized, open-label, prospective trial.

Oncotarget

Wang, Jack P JP; Wu, Chen-Yi CY; Yeh, Yi-Cheng YC; Shyr, Yi-Ming YM; Wu, Ying-Ying YY; Kuo, Chen-Yu CY; Hung, Yi-Ping YP; Chen, Ming-Huang MH; Lee, Wei-Ping WP; Luo, Jiing-Chyuan JC; Chao, Yee Y; Li, Chung-Pin CP

Publication Date: 2015-07-20

Variant appearance in text: EGFR: N842I

PubMed Link: 26046796

Variant Present in the following documents:

• oncotarget-06-18162-s001.pdf

View BVdb publication page

HER family kinase domain mutations promote tumor progression and can predict response to treatment in human breast cancer.

Molecular Oncology

Boulbes, Delphine R DR; Arold, Stefan T ST; Chauhan, Gaurav B GB; Blachno, Korina V KV; Deng, Nanfu N; Chang, Wei-Chao WC; Jin, Quanri Q; Huang, Tzu-Hsuan TH; Hsu, Jung-Mao JM; Brady, Samuel W SW; Bartholomeusz, Chandra C; Ladbury, John E JE; Stone, Steve S; Yu, Dihua D; Hung, Mien-Chie MC; Esteva, Francisco J FJ

Publication Date: 2015-03

Variant appearance in text: EGFR: N842I

PubMed Link: 25435280

Variant Present in the following documents:

• Main text

View BVdb publication page